Chai Discovery says its AI drug design models are used by Eli Lilly, Pfizer, and Novartis
chaitjo · x · 2026-07-29
Chai Discovery says its AI drug design models are now used by Eli Lilly, Pfizer, and Novartis
The post points to an exclusive video about Chai Discovery and its co-founders, Josh Meier and Jack Dent, who left OpenAI and Stripe to build Chai-1/Chai-3, models aimed at designing antibodies in hours rather than years.
Key points from the clip:
- The company claims its models can design antibodies with atomic-level accuracy that has been confirmed in the lab.
- Major pharma companies including Eli Lilly, Pfizer, and Novartis are said to be using the models.
- Chai Discovery has reportedly raised $600M+ from investors including Sequoia, General Catalyst, Thrive Capital, OpenAI, Menlo Ventures, Index Ventures, Kleiner Perkins, and others.
- The video frames the core question as whether AI drug design can materially speed up development for hard diseases.
More from Venture
- Creator marketing pro builds CreatorFlow app with AI coding agent EazoAI from one messy prompt — HeyToha · 2026-10-16
- 10 security vendors rated "cooked" by AI are up 73% in six months, beating S&P's 19% — RealGeneKim · 2026-10-16
- Anthropic IPO math: Amazon+Google set for ~$600B, FTX sold its stake 100x too early — simonada · 2026-10-16
- 7 ChatGPT prompts that turn your skills into side-income ideas, from a viral thread — aitrendz_xyz · 2026-10-16
- China's AI boom drives up to 660% profit surges for domestic chip firms; GPU maker MetaX turns profitable — pstAsiatech · 2026-10-16
- Dev adds Google Merchant Center to his MCP server — and explains how it beats Google's official one — DutchSEOnerd · 2026-10-16